Tislelizumab plus chemotherapy versus chemotherapy alone as first‑line treatment for locally advanced/metastatic nonsquamous NSCLC

 POSTER   09/2020

For more information about this resource, please submit a medical information request.

PD-1 inhibitor tislelizumab plus chemotherapy versus chemotherapy alone as first‑line treatment for locally advanced/metastatic nonsquamous NSCLC

Rating

Rate this resource